Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–13. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial M, Monsour H. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53. doi:10.2147/JHC.S61146.
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. the Lancet. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Farkas S, Hackl C, Schlitt HJ. Overview of the indications and contraindications for liver transplantation. Cold Spring Harb Perspect Med. 2014;4(5):4(5. doi:10.1101/cshperspect.a015602.
   PubMed Web of Science ®Google Scholar
• Koh JH, Tan DJH, Ong Y, Lim WH, Ng CH, Tay PWL, Huang DQ. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr. 2021;11(1): 78–93. doi:10.21037/hbsn-21-350.
   Web of Science ®Google Scholar
• Reveron-Thornton RF, Teng ML, Lee EY, Tran A, Vajanaphanich S, Tan EX, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies. Hepatol Commun. 2022;6(7):1813–1826. doi:10.1002/hep4.1923.
   PubMed Web of Science ®Google Scholar
• Tan DJH, Lim WH, Yong JN, Ng CH, Muthiah MD, Tan EX, Huang DQ. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: systematic Review and Meta-Analysis of 25 Studies Clin Gastroenterol Hepatol. 2022;21(6): 1475–1484. doi:10.1016/j.cgh.2022.02.018.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133.
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0.
   PubMed Web of Science ®Google Scholar
• Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–530. doi:10.1016/S1470-2045(22)00078-X.
   PubMed Web of Science ®Google Scholar
• Tu T, Budzinska M, Maczurek A, Cheng R, Di Bartolomeo A, Warner F, McCaughan G, McLennan S, Shackel N. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15(6):9422–9458. doi:10.3390/ijms15069422.
   PubMed Web of Science ®Google Scholar
• Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis. 2001;21(03):397–416. doi:10.1055/s-2001-17554.
   PubMedGoogle Scholar
• Zheng M, Tian Z. Liver-mediated adaptive immune tolerance. Front Immunol. 2019;10:10. doi:10.3389/fimmu.2019.02525.
   PubMed Web of Science ®Google Scholar
• Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Liang W. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. eClinicalMedicine, 2021. 41.
   Google Scholar
• Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, et al. Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from Cohort 6 of the CheckMate 040 Trial. J Clin Oncol. 2023;41(9):1747–1757. doi:10.1200/JCO.22.00972.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Yau T, Kang Y-K, Kim T-Y, Santoro A, Sangro B, Melero I, Kudo M, Hou M-M, Matilla A, et al. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): long-term results from CheckMate 040. J Clin Oncol. 2021;39(3_suppl):269. doi:10.1200/JCO.2021.39.3_suppl.269.
   PubMed Web of Science ®Google Scholar
• Pathak S, Sonbol MB. Second-line treatment options for hepatocellular carcinoma: current landscape and future direction. J Hepatocell Carcinoma. 2021;8:1147–1158. doi:10.2147/JHC.S268314.
   PubMed Web of Science ®Google Scholar
• Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104(3):413–418. doi:10.1038/sj.bjc.6606074.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Lim HY, Kudo M, Breder V, Merle P, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang Y-K, Qin S, Tai DWM, Lim HY, Yau T, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021;39(27):2991–3001. doi:10.1200/JCO.20.03555.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, et al. Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020;137:272–284. doi:10.1016/j.ejca.2020.06.007.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ikeda M. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO Open. 2018;3:e000455. doi:10.1136/esmoopen-2018-000455.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y-K, Van Dao T, De Toni EN, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8):EVIDoa 2100070. 10.1056/EVIDoa2100070.
   Google Scholar
• Administration UFAD. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. 2018 [accessed 2022 Mar 8]. https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma.
   Google Scholar
• Administration UFAD. FDA approves ramucirumab for hepatocellular carcinoma. 2019 [accessed 2022]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma.
   Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9.
   PubMed Web of Science ®Google Scholar
• Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, Rodriguez L, Schotland P, Chuk M, Davis G, et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. 2021;26(9):797–806. doi:10.1002/onco.13819
   Google Scholar
• Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou M-M, Matilla A, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncology JAMA Oncol. 2020;6(11):e204564. 10.1001/jamaoncol.2020.4564.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808.
   PubMed Web of Science ®Google Scholar
• Finn R, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo B-Y, Ren Z, et al. LBA34 - Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33(suppl_7):S808–869. doi:10.1016/annonc/annonc1089,2022.
   Web of Science ®Google Scholar
• Pompili M, Francica G, Ponziani FR, Iezzi R, & Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19(43):7515–7530. doi:10.3748/wjg.v19.i43.7515.
   PubMed Web of Science ®Google Scholar
• Coletta M, Nicolini D, Cacciaguerra AB, Mazzocato S, Rossi R. Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same? Transl Gastroenterol Hepatol. 2017;2:78. doi:10.21037/2Ftgh.2017.09.01.
   PubMed Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2(9):891–903. doi:10.1038/s43018-021-00234-4.
   PubMedGoogle Scholar
• Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterol Hepatol. 2022;7(3):219–229. doi:10.1016/S2468-1253(21)00385-X.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. doi:10.1016/S1470-2045(15)00198-9.
   PubMed Web of Science ®Google Scholar
• Kudo M. Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma. Liver Cancer. 2021;10(5):399–403. doi:10.1159/000518584.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, Schirmacher P, Vilgrain V. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019.
   PubMed Web of Science ®Google Scholar
• Lee JJX, Tai DWM, Choo SP. Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit. ESMO Open. 2021;6(3):100129.10.1016/j.esmoop.2021.100129
   Google Scholar
• Li X, Wang Y, Ye X, Liang P. locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development. Frontiers In Molecular Biosciences. 2021;8:8. doi:10.3389/fmolb.2021.635243.
   Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595. doi:10.1182/blood-2009-02-206870.
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol. 2015;27(6):445–451. doi:10.1097/CCO.0000000000000225.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712. doi:10.1016/S1470-2045(14)70189-5.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292.
   PubMed Web of Science ®Google Scholar
• Marinelli B, Kim E, D’Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J ImmunoTher Cancer. 2022;10(6):e004205. doi:10.1136/jitc-2021-004205.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. The Lancet Gastroenterology & Hepatology The Lancet Gastroenterol Hepatol. 2023;8(2):169–178. 10.1016/S2468-1253(22)00339-9.
   PubMed Web of Science ®Google Scholar
• Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, Park JS, Dagher NN, Taslakian B, Hickey RM. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31(1):25–34. doi:10.1016/j.jvir.2019.05.023.
   PubMed Web of Science ®Google Scholar
• Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol. 2019;15(4):197–207. doi:10.1038/s41584-019-0188-8.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, Jiang Y, Fang H, Xing S, Fang Y, et al. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med. 2021;13(9):e14291. doi:10.15252/emmm.202114291.
   PubMed Web of Science ®Google Scholar
• Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: functional consequences and design implications. Sci Adv. 2020;6(21). eaaz3223. doi:10.1126/sciadv.aaz3223.
   Web of Science ®Google Scholar
• Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531–550. doi:10.1038/s41573-021-00189-2.
   PubMed Web of Science ®Google Scholar
• Armstrong S, Prins P, He AR. Immunotherapy and immunotherapy biomarkers for hepatocellular carcinoma. Hepatoma Research. 2021;7:18. doi:10.20517/2394-5079.2020.118.
   Google Scholar
• Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol. 2020;155:103109. doi:10.1016/j.critrevonc.2020.103109.
   PubMed Web of Science ®Google Scholar
• Hsu C-H, Lu S, Abbas A, Guan Y, Zhu AX, Aleshin A, Lee K-H, Lee MS, Mahipal A, Ryoo B-Y, et al. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2020;38(15_suppl):3531. doi:10.1200/JCO.2020.38.15_suppl.3531.
   Web of Science ®Google Scholar
• Tang J-C, Feng Y-L, Guo T, Xie A-Y, Cai X-J. Circulating tumor DNA in hepatocellular carcinoma: trends and challenges. Cell & Bioscience. 2016;6(1):32. doi:10.1186/s13578-016-0100-z.
   PubMedGoogle Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. doi:10.1053/j.gastro.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Cai Q, Zhu M, Duan J, Wang H, Chen J, Xiao Y, Wang Y, Wang J, Yu X, Yang H. Comprehensive analysis of immune-related prognosis of TK1 in hepatocellular carcinoma. Front Oncol. 2022;11:11. doi:10.3389/fonc.2021.786873.
   Google Scholar
• Yu Z, Zhang Y, Shao S, Liu Q, Li Y, Du X, Zhang K, Zhang M, Yuan H, Yuan Q, et al. Identification of CDCA2 as a diagnostic and prognostic marker for hepatocellular carcinoma. Front Oncol. 2021;11:11. doi:10.3389/fonc.2021.755814.
   Web of Science ®Google Scholar
• Liu S, Zhao W, Li X, Zhang L, Gao Y, Peng Q, Du C, Jiang N. AGTRAP is a Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma. Front Oncol. 2021;11:11. doi:10.3389/fonc.2021.713017.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? Front Oncol. 2021;11:11. doi:10.3389/fonc.2021.803133.
   Web of Science ®Google Scholar
• Yau T, Park J-W, Finn RS, Cheng A-L, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5.
   PubMed Web of Science ®Google Scholar
• Kim H-D, Song G-W, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology. 2018;155(6):1936–1950.e17. doi:10.1053/j.gastro.2018.08.030.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani E-S, Laurent A, Azoulay D, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–2046. doi:10.1002/hep.28710.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kudo M, Venook AP, Ye S-L, Bronowicki J-P, Chen X-P, Dagher L, Furuse J, Geschwind JFH, de Guevara LL, et al. Observational registry of sorafenib use in clinical practice across child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–1147. doi:10.1016/j.jhep.2016.07.020.
   PubMed Web of Science ®Google Scholar
• Choi WM, Lee D, Shim JH, Kim KM, Lim Y-S, Lee HC, Yoo C, Park SR, Ryu M-H, Ryoo B-Y, et al. Effectiveness and safety of nivolumab in child–Pugh b patients with hepatocellular carcinoma: a real-world cohort study. Cancers (Basel). 2020;12(7):1968. doi:10.3390/cancers12071968.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo S-P, El-Khoueiry AB, Kuromatsu R, El-Rayes B, et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600–609. doi:10.1016/j.jhep.2021.04.047.
   PubMed Web of Science ®Google Scholar
• Yuan L, Feng J, Zhang Y, Lu C, Xu L, Liang C, Liu Z, Mao F, Xiang Y, Wang W, et al. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter cohort study. Eur J Surg Oncol. 2023. doi:10.1016/j.ejso.2023.01.020.
   Web of Science ®Google Scholar
• Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors. Cancers (Basel). 2021;13(24):6307. doi:10.3390/cancers13246307.
   PubMed Web of Science ®Google Scholar
• Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O’Dell H, Perri RE, Alexopoulos SP. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020;20(3):879–883. doi:10.1111/ajt.15617.
   PubMed Web of Science ®Google Scholar
• Schwacha-Eipper B, Minciuna I, Banz V, Dufour JF. Immunotherapy as a Downstaging Therapy for Liver Transplantation. Hepatology. 2020;72(4):1488–1490. doi:10.1002/hep.31234.
   PubMed Web of Science ®Google Scholar
• Chen GH, Wang GB, Huang F, Qin R, Yu XJ, Wu RL, Zhao HC. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66:101386. doi:10.1016/j.trim.2021.101386.
   PubMed Web of Science ®Google Scholar
• Qiao ZY, Zhang Z-J, Lv Z-C, Tong H, Xi Z-F, Wu H-X, Chen X-S, Xia L, Feng H, Zhang J-J, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front Immunol. 2021;12:653437. doi:10.3389/fimmu.2021.653437.
   PubMed Web of Science ®Google Scholar
• Sogbe M, López-Guerra D, Blanco-Fernández G, Sangro B, Narváez-Rodriguez I. Durvalumab as a successful downstaging therapy for liver transplantation in hepatocellular carcinoma: the importance of a washout period. Transplantation. 2021;105(12):e398–400.10.1097/TP.0000000000003855
   Google Scholar
• Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2021;21(5):1979–1980. doi:10.1111/ajt.16448.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267. doi:10.1038/s41571-022-00600-w.
   PubMed Web of Science ®Google Scholar